Enoxaparin was more effective than unfractionated heparin in STEMI, regardless of type of fibrinolytic agent used

November 2007
ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p63
Academic Journal
The article offers information on a study that investigates the effectiveness of enoxaparin, in comparison with unfractionated heparin (UFH), for patients with ST-elevation myocardial infarction (STEMI), irrespective of the type of fibrinolytic agent used. It describes the method and patients' condition for the study. The study revealed that patients with STEMI, enoxaparin reduced risk for nonfatal myocardial infarction, but increased risk for major bleeding.


Related Articles

  • Antithrombotic drugs increase risk of bleeding in myocardial infarction patients.  // Australian Journal of Pharmacy;Apr2010, Vol. 91 Issue 1079, p94 

    The article presents a study on the association of antithrombotic drugs to bleeding in patients with myocardial infarction. Study shows that the drugs increase of bleeding in the patients. It notes that the risk of hospital admission among these patients increased with those with those using...

  • Tenecteplase. Tsikouris, James P.; White, C. Michael // Formulary;Aug2000, Vol. 35 Issue 8, p647 

    Focuses on tenecteplase, a novel fibrin-specific thrombolytic agent approved for the reduction of mortality associated with acute myocardial infarction (AMI). Association with a lower incidence of noncerebral bleeding; Decreased need for blood transfusions compared with alteplase (rt-PA);...

  • Reteplase for Acute Myocardial Infarction.  // American Family Physician;3/1/1997, Vol. 55 Issue 4, p1464 

    Reveals that the United States' Food and Drug Administration has approved the thrombolytic agent reteplase for use in the management of acute myocardial infraction in adults. Information on reteplase; Details on studies conducted on the effect of the drug; Number of patients who participated in...

  • Thrombolytic agent for MI.  // Geriatrics;Feb97, Vol. 52 Issue 2, p28 

    Features reteplase (Retavase), an intravenous thrombolytic agent for the management of acute myocardial infarction. Improvements for ventricular function; Reduction of the incidence of MI-associated congestive heart failure and mortality; Contraindication.

  • PRIMENA NISKOMOLEKULARNIH HEPARINA U AKUTNOM ST ELEVIRANOM INFARKTU MIOKARDA. Petrović, Milovan; Panić, Gordana; Čanji, Tibor; Srdanović, Ilija; Ivanović, Vladimir; Benc, Dragan // Medicinski Pregled / Medical Review;2006, Vol. 59 Issue 9/10, p476 

    Introduction. According to the published guidelines for the management of acute coronary syndromes (ACS), treatment of acute ST-elevated myocardial infarction is based on rapid revascularization, either mechanical or pharmacological. Pharmacological revascularization consists of fibrinolytic...

  • Antithrombotics.  // Reactions Weekly;9/5/2009, Issue 1268, p7 

    The article describes the case of a 59-year-old man who acquired thyroid haemorrhage. The patient developed the said condition while undergoing treatment with antithrombotics, particularly alteplase, heparin, aspirin and clopidogrel, for acute myocardial infarction. He was advised to stop intake...

  • Can BRIGHT Restore the Glow of Bivalirudin? Cavender, Matthew A.; Faxon, David P. // JAMA: Journal of the American Medical Association;4/7/2015, Vol. 313 Issue 13, p1323 

    The authors focus on the results of the Bivalirudin in Acute Myocardial Infarction Versus Heparin and Glycoprotein IIb/IIIa Inhibitors (GPI) Plus Heparin Trial (BRIGHT) conducted by Y. Han and colleagues. The trial studies direct thrombin inhibitor bivalirudin in patients undergoing percutaneous...

  • Therapy of unstable angina with the low molecular weight heparins. Ageno, W.; Turpie, A.G. // Vascular Medicine;2000, Vol. 5 Issue 4, p217 

    Unstable angina is in most cases caused by partial or complete coronary artery occlusion due to the disruption of an atherosclerotic plaque and to thrombus formation. An immediate antithrombotic approach is essential to prevent fatal and non-fatal myocardial infarction, and the combination of...

  • Thrombolysis: a good buy? Smith, Richard // BMJ: British Medical Journal (International Edition);7/23/88, Vol. 297 Issue 6643, p245 

    Examines the efficacy of thrombolytic treatment for acute myocardial infarction. Therapeutic use of the thrombolytic agent for the treatment of mild hypertension; Presence of streptokinase within the thrombolytic agent; Advantages of the agent.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics